Tristan Richard Gordon Sillars
Directeur des opérations chez Arquer Diagnostics Ltd.
Postes actifs de Tristan Richard Gordon Sillars
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Arquer Diagnostics Ltd.
 Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Directeur/Membre du Conseil | - | - |
| Directeur des opérations | - | - | |
| Directeur Financier/CFO | - | - |
Historique de carrière de Tristan Richard Gordon Sillars
Anciens postes connus de Tristan Richard Gordon Sillars
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| KPMG Transaction Services Group | Corporate Officer/Principal | - | - |
Statistiques
Internationale
| Royaume-Uni | 3 |
Opérationnelle
| Director/Board Member | 1 |
| Chief Operating Officer | 1 |
| Director of Finance/CFO | 1 |
Sectorielle
| Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Arquer Diagnostics Ltd.
Arquer Diagnostics Ltd. Medical/Nursing ServicesHealth Services Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom. | Health Services |
| KPMG Transaction Services Group |
